| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5883016 | Clinical Lymphoma Myeloma and Leukemia | 2013 | 7 Pages |
Abstract
Treatment with VTEPA for R/R HL is feasible with manageable side effects. With a high ORR, the PFS and OS for this group of patients suggest that VTEPA is a promising regimen for HL patients in whom previous lines of therapy have failed.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Rajni Sinha, Pareen J. Shenoy, Nassoma King, Mary Jo Lechowicz, Kevin Bumpers, Donald Hutcherson, Martha Arellano, Amelia Langston, Jonathan Kaufman, Leonard T. Jr., Edmund K. Waller, Ajay Nooka, Christopher R. Flowers, Sagar Lonial,